Stephen M. Stahl, M.D., Ph.D.

Article

Introduction. What Makes an Antipsychotic Atypical?

October 1, 1999

Article

Selecting an Atypical Antipsychotic by Combining Clinical Experience With Guidelines From Clinical Trials

October 1, 1999

Brainstorms

Molecular Neurobiology for Practicing Psychiatrists, Part 1: Overview of Gene Activation by Neurotransmitters

September 30, 1999

Brainstorms

Antipsychotic Polypharmacy, Part 2: Tips on Use and Misuse

August 1, 1999

Brainstorms

Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret?

July 1, 1999

Brainstorms

Antidepressants: The Blue-Chip Psychotropic for the Modern Treatment of Anxiety Disorders

June 30, 1999

Brainstorms

Mergers and Acquisitions Among Psychotropics: Antidepressant Takeover of Anxiety May Now Be Complete

May 1, 1999

Brainstorms

Why Settle for Silver, When You Can Go for Gold? Response vs. Recovery as the Goal of Antidepressant Therapy.

April 30, 1999

Brainstorms

Peptides and Psychiatry, Part 3: Substance P and Serendipity: Novel Psychotropics Are a Possibility

March 31, 1999

Brainstorms

Substance P and the Neurokinins: Novel Peptide Neurotransmitters in Psychopharmacology

February 28, 1999

Brainstorms

Peptides and Psychiatry, Part 1: How Synthesis of Neuropeptides Differs From Classical Neurotransmitter Synthesis

January 31, 1999

Brainstorms

Using Secondary Binding Properties to Select a Not So Selective Serotonin Reuptake Inhibitor

December 15, 1998